drugset / Trial / NCT05804383
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
Phase 1
Completed
51 enrolled
Allyx Therapeutics
National Institute on Aging (NIA) · collabYale University · collab
RandomizedParallel-groupTriple-blindBasic science
Summary
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Timeline
- Start
- 2023-03-28
- Primary completion
- 2025-07-15
- Completion
- 2025-10-15
Publications
- Background Haas LT, Salazar SV, Smith LM, Zhao HR, Cox TO, Herber CS, Degnan AP, Balakrishnan A, Macor JE, Albright CF, Strittmatter SM. Silent Allosteric Modulation of mGluR5 Maintains Glutamate Signaling while Rescuing Alzheimer's Mouse Phenotypes. Cell Rep. 2017 Jul 5;20(1):76-88. doi: 10.1016/j.celrep.2017.06.023.
- Background Spurrier J, Nicholson L, Fang XT, Stoner AJ, Toyonaga T, Holden D, Siegert TR, Laird W, Allnutt MA, Chiasseu M, Brody AH, Takahashi H, Nies SH, Perez-Canamas A, Sadasivam P, Lee S, Li S, Zhang L, Huang YH, Carson RE, Cai Z, Strittmatter SM. Reversal of synapse loss in Alzheimer mouse models by targeting mGluR5 to prevent synaptic tagging by C1Q. Sci Transl Med. 2022 Jun;14(647):eabi8593. doi: 10.1126/scitranslmed.abi8593. Epub 2022 Jun 1.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-984923 | Small molecule | 50 mg | — |
| Subject | BMS-984923 | Small molecule | 100 mg | — |
| Subject | BMS-984923 | Small molecule | 150 mg | — |